Longley, Daniel B.

5-Fluorouracil: mechanisms of action and clinical strategies

Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer

Colorectal Cancer Treatments and StudiesCancer therapeutics and mechanisms

Cited by 5,332

Cancer drug resistance: an evolving paradigm

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer

Drug Transport and Resistance MechanismsCancer Cells and Metastasis

Cited by 4,681

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

Van Schaeybroeck, S., Kalimutho, M., Dunne, P. D., Carson, R., Allen, W., Jithesh, P. V., Redmond, K. L., Sasazuki, T., Shirasawa, S., Blayney, J., et al. (2014) · Cell Reports

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 106

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer

Kyula, J. N., Van Schaeybroeck, S., Doherty, J., Fenning, C. S., Longley, D. B., & Johnston, P. G. (2010) · Clinical Cancer Research

Protease and Inhibitor MechanismsColorectal Cancer Treatments and Studies

Cited by 99

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

Turkington, R. C., Longley, D. B., Allen, W. L., Stevenson, L., McLaughlin, K., Dunne, P. D., Blayney, J. K., Salto-Tellez, M., Van Schaeybroeck, S., & Johnston, P. G. (2014) · Cell Death & Disease

Fibroblast Growth Factor ResearchColorectal Cancer Treatments and Studies

Cited by 98

Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification

Dunne, P. D., Alderdice, M., O'Reilly, P. G., Roddy, A. C., McCorry, A. M. B., Richman, S., Maughan, T., McDade, S. S., Johnston, P. G., Longley, D. B., et al. (2017) · Nature Communications

Gene expression and cancer classificationColorectal Cancer Treatments and Studies

Cited by 94

Differential affinity of FLIP and procaspase 8 for FADD’s DED binding surfaces regulates DISC assembly

Majkut, J., Sgobba, M., Holohan, C., Crawford, N., Logan, A. E., Kerr, E., Higgins, C. A., Redmond, K. L., Riley, J. S., Stasik, I., et al. (2014) · Nature Communications

Cell death mechanisms and regulationNF-κB Signaling Pathways

Cited by 81

Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours

McDaid, W. J., Greene, M. K., Johnston, M. C., Pollheimer, E., Smyth, P., McLaughlin, K., Van Schaeybroeck, S., Straubinger, R. M., Longley, D. B., & Scott, C. J. (2019) · Nanoscale

Nanoparticle-Based Drug DeliveryPancreatic and Hepatic Oncology Research

Cited by 58

Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17

Van Schaeybroeck, S., Kyula, J. N., Fenton, A., Fenning, C. S., Sasazuki, T., Shirasawa, S., Longley, D. B., & Johnston, P. G. (2011) · Cancer Research

Protease and Inhibitor MechanismsProtein Kinase Regulation and GTPase Signaling

Cited by 51

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant

Fichtner, M., Bozkurt, E., Salvucci, M., McCann, C., McAllister, K. A., Halang, L., Düssmann, H., Kinsella, S., Crawford, N., Sessler, T., et al. (2020) · Cell Death & Disease

Cell death mechanisms and regulationColorectal Cancer Treatments and Studies

Cited by 28

Therapeutics Targeting the Core Apoptotic Machinery

Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 26

Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711

Crawford, N., Salvucci, M., Hellwig, C. T., Lincoln, F. A., Mooney, R. E., O’Connor, C. L., Prehn, J. H., Longley, D. B., & Rehm, M. (2018) · Cell Death & Differentiation

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 22

Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer

Corry, S. M., McCorry, A. M., Lannagan, T. R., Leonard, N. A., Fisher, N. C., Byrne, R. M., Tsantoulis, P., Cortes-Lavaud, X., Amirkhah, R., Redmond, K. L., et al. (2022) · Gut

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 18